Braveheart Bio, Inc. (BRVE)
NASDAQ: BRVE · Real-Time Price · USD
19.55
+0.21 (1.09%)
At close: Oct 15, 2026, 4:00 PM EDT
19.27
-0.28 (-1.43%)
After-hours: Oct 15, 2026, 7:30 PM EDT
Braveheart Bio Earnings Call Transcripts
Fiscal Year 2026
-
The forum highlighted strong clinical progress in HCM, with BHB-1893 showing rapid, deep efficacy and a differentiated safety profile. Simplified dosing, positive regulatory feedback, and robust financials position the program for global phase III advancement and potential early filing.
-
Lead asset BHB-1893 has shown promising phase II results in both obstructive and non-obstructive HCM, with significant biomarker and structural improvements. Global phase III trials are underway, aiming for simplified dosing and broader market adoption, supported by a robust regulatory and financial strategy.